Annual report
4587.TEDINET S100XRP4
Period2025-01-01 → 2025-12-31
Filed2026-03-18
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.5bn | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥46.7bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥28.7bn | 2023-01-01 → 2023-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | −¥5.0bn | 2025-01-01 → 2025-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥21.1bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥5.3bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥20.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.4bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.8bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | −¥3.7bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.0bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | −¥3.7bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥77.0bn | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥92.8bn | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥69.5bn | at 2023-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥63.9bn | at 2022-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥27.0bn | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥25.5bn | at 2025-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥36.0bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥51.5bn | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥56.8bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.3bn | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥51.5bn | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥56.8bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥40.3bn | at 2023-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥32.0bn | at 2022-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥25.4bn | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥28.7bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥48.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.5bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥13.3bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥23.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥12.4bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥8.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥1.3bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥4.1bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥3.0bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥264m | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥-28.99 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥115.85 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.41 | 2023-01-01 → 2023-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥19.96 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-28.99 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥115.68 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.38 | 2023-01-01 → 2023-12-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.81 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥398.53 | at 2025-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥437.63 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥311.16 | at 2023-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥246.63 | at 2022-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥195.1 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 66.9% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.2% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 58.1% | at 2023-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | -6.9% | 2025-01-01 → 2025-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 30.9% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.4% | 2023-01-01 → 2023-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 26.3% | 2022-01-01 → 2022-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.0% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 645 | at 2025-12-31 | Cons. | Number of employees |
| Employees | 621 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 603 | at 2023-12-31v | Cons. | Number of employees |
| Employees | 569 | at 2022-12-31v | Cons. | Number of employees |
| Employees | 141 | at 2021-12-31d | Cons. | Number of employees |
| Revenue | ¥2.8bn | 2025-01-01 → 2025-12-31 | Standalone | Net sales |
| Revenue | ¥31.3bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥12.7bn | 2023-01-01 → 2023-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥15.4bn | 2022-01-01 → 2022-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥5.3bn | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | ¥21.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | −¥5.3bn | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥20.5bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.4bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.8bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥6.1bn | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥29.8bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | −¥5.4bn | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | ¥21.1bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥5.8bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.3bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.6bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥70.1bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥89.7bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥68.2bn | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥55.2bn | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥26.6bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥20.7bn | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥34.1bn | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥49.4bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥55.6bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥40.6bn | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥29.4bn | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥25.0bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥24.3bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥44.6bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-41.93 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥162.6 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.85 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.11 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.98 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2021-01-01 → 2021-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥381.72 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥428.73 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥312.89 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥226.48 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥192.39 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 70.4% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.0% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.5% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.2% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -10.3% | 2025-01-01 → 2025-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 43.8% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.6% | 2023-01-01 → 2023-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.8% | 2022-01-01 → 2022-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.6% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 130,010,400 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 169 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 157 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 153 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 155 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 141 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-12-31 | −¥1.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-12-31 | −¥1.2bn |
| Drug Discovery And Development Businessreportable segment | employees | at 2025-12-31 | 169 pure |
| Drug Discovery And Development Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥2.8bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥2.8bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | −¥5.4bn |
| Radiopharmaceuticals Businessreportable segment | employees | at 2025-12-31 | 476 pure |
| Radiopharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥16.9bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥15.7bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥1.2bn |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥435m |
| —segment total | revenue | 2025-01-01 → 2025-12-31 | ¥19.7bn |
| —segment total | revenue external | 2025-01-01 → 2025-12-31 | ¥18.5bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥1.2bn |
| —segment total | segment profit | 2025-01-01 → 2025-12-31 | −¥4.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥741m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥741m |
| Drug Discovery And Development Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥31.3bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥31.3bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥21.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥16.1bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥15.4bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥741m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥247m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥47.4bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥46.7bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥741m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥21.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,493
| Item | Context | Value | Unit |
|---|---|---|---|
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 3908586000 | JPY |
| Research and development expenses sga | Prior1YearDuration_NonConsolidatedMember | 3262827000 | JPY |
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 3908586000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-03-18 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第20期(自 2025年１月１日 至 2025年12月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ペプチドリーム株式会社 | |
| Company name in english cover page | FilingDateInstant | PeptiDream Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO リード・パトリック | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 044-270-1300 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)IR広報ディレクター 沖本 優子 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 044-223-6612 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)IR広報ディレクター 沖本 優子 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E27486 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45870 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ペプチドリーム株式会社 | |
| Filer name in english | FilingDateInstant | PeptiDream Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2025-01-01 | |
| Current period end date | FilingDateInstant | 2025-12-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2025-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Comparative period end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |